Reports Q2 revenue $21.76M, consensus $39.83M. “The second quarter was a clear demonstration of our strategy in action. Our team delivered another solid quarter of performance, even as U.S. Academic spend remained under pressure, while taking meaningful steps to transform the business,” said Michael Egholm, president and CEO of Standard BioTools (LAB). “The announced sale of SomaLogic to Illumina marks a pivotal milestone in that evolution – unlocking up to $425 million in total cash consideration with additional upside levers and further validating the power of our model.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LAB:
- LAB Upcoming Earnings Report: What to Expect?
- Standard BioTools, Precision Health, Singapore launch proteomic collaboration
- Standard BioTools Approves Stock Awards for Executives
- Standard BioTools Sells Subsidiaries to Illumina
- U.S. strikes Iran nuclear sites, Novo terminates Hims & Hers deal: Morning Buzz